Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : KPTI save search
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-01 (Crawled : 20:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -1.9%
H: 0.65%
C: -10.0%
nasdaq grants therapeutics
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.26%
H: 18.38%
C: 12.5%
biopharma global
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Published: 2024-02-29 (Crawled : 12:30) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.0%
H: 2.26%
C: -12.78%
company year financial results
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Published: 2024-02-22 (Crawled : 15:30) - biospace.com/
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.83%
H: 2.05%
C: -7.38%
report year financial results
PARP Inhibitors Market to reach over USD 10.31 billion by the year 2031 - Exclusive Report by InsightAce Analytic
Published: 2024-02-21 (Crawled : 09:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.88%
H: 1.75%
C: -0.29%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -1.65%
H: 3.36%
C: 1.68%
CKPT | $1.47 -8.13% -8.84% 760K
|
Health Technology
|
| O: 0.0%
H: 1.26%
C: -3.03%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.01%
H: 1.1%
C: 1.1%
report year reach market
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 1.08%
H: 18.52%
C: 14.29%
nasdaq grants therapeutics
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.14%
H: 10.9%
C: 9.56%
revenue
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 12:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.98%
H: 1.1%
C: -8.45%
conference
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-02 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.98%
H: 1.1%
C: -8.45%
nasdaq grants therapeutics
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
Published: 2023-12-14 (Crawled : 02:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 3.07%
H: 9.75%
C: 5.02%
xpovio drug
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
Published: 2023-12-11 (Crawled : 02:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -1.36%
H: 12.13%
C: -8.31%
durability study
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2023-12-06 (Crawled : 09:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 0.81%
H: 8.51%
C: 3.74%
xpovio approval treatment
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
Global Glioma Treatment Market Research Report 2023: Breakthrough Oncolytic Virus Therapy Offers New Hope for Glioma Patients - Forecast to 2027 and 2032
Published: 2023-11-27 (Crawled : 23:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 4.0%
H: 1.93%
C: -7.72%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.03%
H: 0.85%
C: 0.44%
report hope treatment research global virus therapy market
Karyopharm to Participate at Upcoming Investor Conferences
Published: 2023-11-08 (Crawled : 21:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 3.05%
H: 0.17%
C: -10.3%
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
Published: 2023-11-06 (Crawled : 12:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 3.4%
H: 5.47%
C: -4.36%
tp53 cancer study
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 1.78%
H: 6.8%
C: -4.86%
meeting
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.39%
H: 0.32%
C: -0.93%
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.92%
H: 6.08%
C: -3.35%
collaboration trial
Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
Published: 2023-10-26 (Crawled : 14:00) - biospace.com/
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.71%
H: 3.0%
C: -3.47%
report financial results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.